ANKEBIO BEVACIZUMAB

【澳门博彩娱乐官方网站】Bevacizumab， biosimilar of Avastion

【银河博彩】Non-small cell lung cancer

【银河博彩】Monoclonal antibody

【银河博彩】

Bevacizumab acts by selectively binding circulating VEGF, thereby inhibiting the binding of VEGF to its cell surface receptors. This inhibition leads to a reduction in microvascular growth of tumor blood vessels and thus limits the blood supply to tumor tissues. These effects also lower tissue interstitial pressure, increase vascular permeability, may increase delivery of chemotherapeutic agents, and favor apoptosis of tumor endothelial cells